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Solution structure and peptide binding of the SH3 domain from
human Fyn
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Debora AC Renzoni2 and Iain D Campbell1*
Background:  The Src family of tyrosine kinases is involved in the propagation of
intracellular signals from many transmembrane receptors. Each member of the
family contains two domains that regulate interactions with other molecules, one
of which is the Src homology 3 (SH3) domain. Although structures have
previously been determined for SH3 domains, and ideas about peptide-binding
modes have been proposed, their physiological role is still unclear.
Results:  We have determined the solution structure of the SH3 domain from the
Src family tyrosine kinase Fyn in two forms: unbound and complexed with a
peptide corresponding to a putative ligand sequence from phosphatidylinositol 3′
kinase. Fyn SH3 shows the typical SH3 topology of two perpendicular three-
stranded b sheets and a single turn of 310 helix. The interaction of SH3 with three
potential ligand peptides was investigated, demonstrating that they all bind to the
same site on the molecule. A previous model for ligand binding to SH3 domains
predicts binding in one of two orientations (class I or II), each characterized by a
consensus sequence. The ligand with the closest match to the class I
consensus sequence bound with highest affinity and in the predicted orientation. 
Conclusions:  The Fyn SH3 domain has a well-defined structure in solution. The
relative binding affinities of the three ligand peptides and their orientation within
the Fyn SH3 complex were consistent with recently proposed models for the
binding of ‘consensus’ polyproline sequences. Although the affinities of
consensus and non-consensus peptides are different, the degree of difference is
not very large, suggesting that SH3 domains bind to polyproline peptides in a
promiscuous manner.
Introduction
The Src family of tyrosine kinases associate with the cyto-
plasmic face of the plasma membrane [1] and play a key
role in the signalling cascade by binding to activated
receptor molecules. Fyn, a member of the Src family, is
expressed in a wide variety of cell types and is found in
one of two isoforms as a result of alternative splicing at the
start of its kinase domain [2]. In T cells, Fyn is known to
interact with the TCRz/CD3 part of the activated T-cell
receptor complex [3], but also appears to play some part in
mitotic events [4]. Like all Src family members, Fyn inter-
acts with other proteins through two conserved amino-acid
motifs, the Src homology 2 (SH2) and SH3 domains. The
role of the SH2 domain is relatively well understood — it
binds to phosphorylated tyrosine residues on target mol-
ecules — but that of the SH3 domain is less clear. It is
widely accepted that SH3 domains bind to polyproline
sequences but so far few in vivo SH3 activities have been
clearly defined, let alone characterized structurally
(reviewed in [5]). In contrast, structural studies carried out
in vitro with SH3 domains produced either synthetically or
from cloned material have been very successful. Structures
have been determined by both X-ray crystallography and
NMR [6–17], including complexes with polyproline pep-
tides [6,16,17]. All of these structures show the same basic
topology: a compact b barrel of five antiparallel b strands
in two orthogonal sheets of three strands (with one strand
shared by both sheets).The polyproline-binding site was
initially identified by chemical-shift analysis of peptide
complexed Src [7] and p85a ([11], a subunit of phos-
phatidylinositol 3-kinase, PI3′ kinase). This putative
ligand-binding region — a conserved patch of hydropho-
bic residues on the surface of the molecule — was subse-
quently confirmed by the determination of SH3–peptide
complex structures [6,16,17]. X-ray structures have also
been determined for the entire Grb2 molecule [18] and
the SH3–SH2 double domain from Lck [9], revealing that
the structure of SH3 domains appears to be independent
of neighbouring modules.
Many recent studies of SH3–peptide interactions have
made use of synthetic peptides corresponding to ligands
of unknown biological relevance, the goal being to design
peptides that show high affinity to SH3 [19]. Table 1
Addresses:  1Oxford Centre for Molecular
Sciences, South Parks Road, Oxford, OX1 3QY,
UK and 2Dipartimento di Chimica, Universit  di
Siena, Pian dei Mantellini 44, 53100 Siena, Italy.
†CJM and DJRP contributed equally to this work.
*Corresponding author. E-mail:  idc@bioch.ox.ac.uk
Key words: Fyn, NMR, peptide binding, protein
structure, SH3
Received:  1 Mar 1996
Revisions requested:  19 Mar 1996
Revisions received:  1 April 1996
Accepted:  16 April 1996
Structure 15 June 1996, 4:705–714
© Current Biology Ltd ISSN 0969-2126
Research Article 705
contains a summary of the various peptide ligands that
have been used in published SH3–binding experiments.
Of these, only three make use of fragments of molecules
known to be physiologically significant. The first struc-
tures of SH3–peptide complexes revealed an unexpected
complication: different peptides were found that bound in
opposite orientations on the same SH3 domain (reviewed
in [20]). A model explaining this behaviour was suggested
by two different groups [21,22]. In both orientations, the
peptide ligand assumes a left-handed polyproline II
(PPII) helix, allowing the proline residues to adopt their
preferred backbone angles (f=–75° and c=145°). This
structure is not uncommon on the surface of globular pro-
teins and, due to its conformational stability, may have
evolutionary advantages as a binding site [23]. The orien-
tation of the ligand is defined by the non-prolyl side
chains in the peptide, particularly the position of a critical
arginine. A salt bridge forms between the arginine and a
highly conserved carboxyl group in the protein. Due to
the symmetry of the PPII helix, the majority of the ligand
interacts with equal facility in either orientation, while the
actual orientation is defined by the position of the arginine
residue at either the N-terminal or C-terminal end of the
polyproline sequence and the resultant placement of the
salt bridge. This model allows ligands to be divided into
two groups. Class I ligands have the consensus sequence
RXXPXXP and bind in one orientation, whereas class II
ligands have the consensus PXXPXR and bind the other
way around [22]. The other residues in the ligands that
interact with the protein are R+2, R+3, R+5 and R+6 in
class I peptides and R–2, R–3, R–5 and R–6 in class II
peptides, where R+n is the nth residue after the critical
arginine (positive numbering refers to residues C-terminal
to the arginine, and vice versa).
Here, we describe the solution structure of the Fyn SH3
domain and compare it with other known SH3 structures, in
particular the structures of the Fyn SH3 domain deter-
mined by X-ray crystallography [8]. The high quality of this
solution structure has allowed the clarification of some
ambiguities present in the X-ray data. In addition to the
solution structure of the protein alone, we describe studies
of the interaction of the SH3 domain with three peptides
corresponding to putative ligand sequences and the struc-
ture of the complex between Fyn SH3 and one of these
peptides. The ligand peptides are derived from residues
80–104 of the p85a subunit of PI3′ kinase, which have been
implicated as a binding site in vivo [24]. Binding of the Fyn
SH3 domain to p85a increases the PI3′ kinase activity of
the enzyme by more than a factor of five and this activation
is blocked by the presence of a synthetic peptide corre-
sponding to residues 80–104 of p85a [24]. Our data support
the current model of SH3–ligand interactions and provide
insights into the role of other residues in a class I peptide.
Results
Solution structure
We have determined the three-dimensional structure in
solution of the Fyn SH3 domain, residues 82–148 of the
Fyn protein, in 10 mM phosphate, pH 6.0 at 30°C. Under
these conditions, the protein remained completely stable
for several months, whereas at lower pH values (pH<5.8)
it tended to aggregate over time (data not shown). Reso-
nance assignments were made primarily from 3D 15N-sep-
arated TOCSY (total correlation spectroscopy) and
15N-separated NOESY (nuclear Overhauser effect spec-
troscopy) combined with homonuclear 2D TOCSY and
NOESY data sets. DQF-COSY (double quantum-filtered
correlation spectroscopy ) spectra were used to confirm
some spin system assignments. The expressed clone
covered residues 82–148 of the Fyn sequence, with an
additional Gly–Ser at the N terminus resulting from the
expression system (69 residues in total) (Fig. 1). Complete
assignments were obtained for the majority of the protein,
the exceptions being the four N-terminal and seven C-ter-
minal residues of the molecule. Sequential connectivities
were absent for the spin systems tentatively assigned to
these terminal residues and consequently these assign-
ments could not be confirmed. The lack of connectivities
for these residues suggested they were unstructured, and
when this was supported by the inspection of preliminary
structures these residues were excluded from subsequent
structure calculations. 
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Table 1
Summary of the origin of ligands used in SH3–ligand binding
studies.
SH3 domain Source of ligand Structure of complex Reference
N-Grb2 Sos* Yes [15]
Sos* Yes [41]
C-Grb2 Sos* No [16]
Abl 3BP-1, 3BP-2 No [42]
3BP-1, 3BP-2 Yes [6]
Several† No [43]
Fyn p85a Yes This work
3BP-2 Yes [6]
Several† No [43]
cSrc Random synthesis‡ Yes [22]
Several† No [43]
Random synthesis§ No [19]
nSrc Several† No [43]
a-spectrin Several† No [43]
p85 dynamin No [11]
Random synthesis‡ Yes [17]
cSem5 Sos# Yes [21]
cCrk C3G** Yes [44]
*Peptide VPPPVPPRRR. †This study involved the use of 7 different
putative ligands: one each from 3BP-1 and 3BP-2, two from p85a
(residues 299–311 and 88–98, which include part of the peptides 1
and 2 used in this study), two from Sos, and P10, a 10-residue
peptide containing only prolines. ‡Ligand was selected on the basis of
high affinity for SH3, from a random synthetic peptide mixture.
§Ligands were selected on the basis of high affinity, from a peptide-
based random synthesis with non-standard amino acid monomers.
#Peptide PPPVPPRRR. **PPPALPPKKR
Structures were calculated by dynamical simulated
annealing in the program X-PLOR 3.1 [25], using a total of
588 nuclear Overhauser effect (NOE) distance constraints,
46 constraints for 23 backbone hydrogen bonds and 35
dihedral angle constraints (Fig. 1). Figure 2a shows a
superposition of the final 20 Fyn SH3 structures and
Figure 2b shows a stereodiagram of the representative
structure. The root mean square deviation (rmsd) of the
final structures over the backbone atoms is 0.59 Å for all
residues and 0.37 Å for the well-defined regions (residues
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Figure 1
Summary of the sequence and structural
details of the Fyn SH3 domain. (a) Schematic
representation of the Fyn tyrosine kinase
showing the location of the SH3 domain
relative to the SH2 and kinase domains. The
sequence of the 69 residue cloned protein,
comprising residues 82–148 of Fyn and an
N-terminal Gly–Ser extension (underlined,
numbered as 80 and 81), is shown. The
position and identity of each of the five
b strands (black bars) and the 310 helix
(striped bar) are shown beneath the
sequence. (b) Histogram showing the number
of significant NOE constraints per residue
used in the structure calculations. NOEs are
grouped into intraresidue, sequential (i–j=1),
medium (i–j<5) and long range (i–j≥5). 
(c) Histogram of the average atomic rmsd
between the final 20 structures and the
average structure. The four N-terminal and
seven C-terminal residues were excluded from
final structure calculations. (d) Graph of the
15N-1H NOE values for the backbone amides
of each residue. Proline residues (134 and
140) have no amide proton and are not
shown. Assignments for amide resonances of
residues 80–83 and 142–148 are uncertain
and they are not shown.
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85–113 and 119–141). Structural statistics for the family of
structures and the minimized average structure are given
in Table 2. As with other SH3 structures, the topology of
the Fyn SH3 domain consists of two triple-stranded,
antiparallel b sheets forming a sandwich with the strands
of one sheet at right angles to those in the other and a
single turn of 310 helix (Fig. 3). The first sheet, bI, con-
tains strands ba, bb1 and be; the second sheet, bII, is
made up of strands bb2, bc and bd (Figs 1,3). The back-
bone dynamics of the protein were measured using
15N-1H NOE experiments at 600 MHz. As can be seen
from Figure 1d, the only significant flexibility in the
protein, apart from the N and C termini (data only shown
for the N terminus), occurs in the vicinity of Gly117.
Structure of the SH3–peptide complex
We have also determined the structure of Fyn SH3 com-
plexed with a synthetic peptide corresponding to a putative
SH3-binding sequence from the p85a subunit of PI3′
kinase. This peptide, peptide 2, corresponds to residues
91–104 (PPRPLPVAPGSSKT) of p85a. Although the
affinity of the SH3 domain for the ligand peptide was
found to be relatively low (see below), a number of inter-
molecular NOE peaks were found in spectra of the
SH3–peptide 2 complex. The observed NOEs are sum-
marised in Table 3. Most significant were those observed
between the arginine and alanine residues of peptide 2 and
the side chains of Trp119 and Tyr91, respectively, in Fyn
SH3. These interactions alone define the binding to be
class I. Although insufficient to allow a complete structure
calculation of the SH3–peptide complex, the measurable
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Figure 2
Solution structure of the SH3 domain from
human Fyn. (a) A stereoview of a
superimposition of the final 20 structures of
Fyn SH3. Backbone atoms for residues
84–141 are shown in green, with the side
chain heavy atoms of the phenylalanine,
tyrosine and tryptophan residues shown in
red. The rmsd for the backbone atoms is
0.59 Å over all residues and 0.37 Å over the
residues in regions of well defined secondary
structure. Residue numbers are given for
every tenth amino acid. (b) Stereofigure of the
representative SH3 structure. Backbone
atoms are shown, with every tenth residue
(starting at residue 90) indicated.
Table 2
Structural statistics for the family of 20 Fyn-SH3 structures and
the average structure. Values are the rmsd from experimental
or idealized data.
Structural property* NMR family Average structure
NOE-derived constraints (Å)
All (588) 0.0035(7) 0.0081
Long range (295) 0.0032(8) 0.0090
Short range (55) 0.0023(16) 0.0082
Sequential (135) 0.0036(16) 0.0086
Intraresidue (103) 0.0035(16) 0.0034
Other experimental constraints
hydrogen-bond lengths (46; Å) 0.0047(18) 0.0032
f-constraints (35; °) 0.0024(23) 0
Idealised geometry†
Ideal bond lengths (Å) 0.00179(4) 0.00173
Ideal angles (°) 0.382(4) 0.372
Impropers (°) 0.195(6) 0.177
The numbers in parentheses indicate the number of constraints in each
category. †Comparison with the idealised geometry used by X-PLOR 3.1. 
constraints provide enough data to build a peptide ligand
onto the unbound SH3 structure. A structure calculated in
this way shows that the peptide binds across the protein as
a PPII helix in a class I orientation (Fig. 4). This orientation
supports the recently presented models for peptide–SH3
interaction in which the position of the arginine residue in
the peptide is critical for determining the peptide align-
ment [21,22].
Peptide binding
In addition to the structure of the SH3–peptide 2 complex,
we have investigated the interaction of the Fyn SH3
domain with two other synthetic peptides corresponding
to potential SH3-binding sequences. The first, peptide 1
corresponds to residues 80–93 from the p85a subunit of
PI3′ kinase (KKISPPTPKPRPPR) and the second is iden-
tical to peptide 2, with the exception of a single Leu→Thr
mutation (peptide 3; PPRPTPVAPGSSKT). This substi-
tution was selected on the basis that a change from a bulky
hydrophobic side chain to a bulky hydrophilic side chain is
likely to have a significant, but localized, effect on binding.
Graphs of residue number versus the difference in both
the 15N and 1H chemical shifts of the SH3 amide reso-
nances on addition of these peptides (Fig. 5) indicate that
peptide–protein interaction is occurring with the same
region of the SH3 domain, regardless of the peptide
sequence. In the absence of solution structures for all
three SH3–peptide complexes, variations in the chemical-
shift changes on peptide binding allow further details of
the weaker interactions to be deduced. In themselves, the
chemical-shift changes do not provide any information as
to the binding orientation of the peptides and subse-
quently it is not possible to suggest a binding orientation
for peptide 1; however, for peptide 3 the structure of the
SH3–peptide 2 complex coupled with comparison of the
chemical-shift changes observed for these two ligands
allows a prediction of a class I orientation to be made.
Contacts between the leucine residue in peptide 2 and the
SH3 domain occur through the SH3 residues Gly117,
Asp118, Trp119, Pro134, Ser135, Asn136 and Tyr137.
Consequently, if peptide 3 interacted with the protein in
an identical fashion, the greatest differences in the pattern
of chemical-shift changes should occur for these residues
as a result of the leucine→threonine mutation. As shown
in Figure 5, this appears to be the case. 
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Figure 3
Diagrammatic representation of the Fyn SH3 structure, showing the
position of the two b sheets and the single turn of 310 helix. Strands
are coloured green in b sheet I and yellow in b sheet II, with the 310
helix coloured blue. The N and C termini are indicated. This figure was
prepared with the programs MOLSCRIPT [45] and Raster3D [46,47].
Table 3
Summary of the NOE peaks observed between the Fyn SH3
domain and peptide 2. 
Peptide 2 atoms Fyn SH3 atoms
Arg3 CbH, CgH Trp119 C(2)H, N(1)H
Leu5 CaH Trp119 N(1)H, C(7)H
Pro6 CdH Trp119 N(1)H, C(7)H
Pro6 CgH Tyr137 C(2,6)H, C(3,5)H
Ala8 CbH Tyr91 C(2,6)H, Asn136 CdH, Tyr137 C(2,6)H
Pro9 CdH Tyr137 C(2,6)H
Figure 4
The structure of the Fyn SH3–peptide 2 complex. The protein is
shown as a backbone worm, with residues displaying NOE crosspeaks
with the peptide shown as sticks. These are Tyr91 (red), Tyr137
(cyan), Asn136 (yellow) and Trp119 (green). The peptide is displayed
as a ball and stick structure, coloured by atom type, with the
N terminus on the right of the picture.
Binding curves were determined by titrating each peptide
into separate samples of 15N SH3 and acquiring 15N-1H
HSQC spectra at several different peptide:protein ratios
(see the Materials and methods section). A plot of change
in chemical shift versus peptide:protein ratio for various
resonances (Fig. 6) shows that the technique clearly differ-
entiates between the three peptides. Identical results can
be achieved from analysis of both backbone and side-chain
amide resonances: Figure 6a,b shows the results for back-
bone amide resonances of Thr97 and Trp119 respectively,
while Figure 6c shows the data for the side-chain amide 
of Asn136. Similarly, the results for 15N (Fig. 6c) and 
1H (Fig. 6a,b) chemical shifts are identical. Non-linear
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Figure 5
Histograms of the change in amide resonance chemical shifts upon
peptide binding for (a) peptide 1, (b) peptide 2 and (c) peptide 3.
Values are normalized so that the largest change is equal to 1 for all
three peptides. Shaded bars represent 1H chemical shift changes,
unfilled bars represent 15N chemical shift changes. Proline residues
lack an amide proton and are not shown.
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Figure 6
Binding curves for the interaction of SH3 with peptides 1, 2 and 3. In
each plot the top curve corresponds to peptide 2, the middle to peptide
3 and the bottom to peptide 3. The change in chemical shift at different
protein:peptide ratios is shown, normalised to 1 for fully bound SH3: (a)
the amide 1H shift of Thr97; (b) the amide 1H shift of Trp119; and (c)
the side-chain amide 15N shift of Asn136. Curves shown were derived
by non-linear regression analysis of each data set, fitting to an equation
relating change in chemical shift to the peptide:protein ratio. These data
were chosen as representative results; similar curves could be
determined for several other resonances.
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regression analysis of the data allowed the derivation of Kd
values for each interaction. The Kd values measured in
this way are 3 mM, 50 mM and 300 mM for peptides 1, 2
and 3 respectively.
Discussion
SH3 structure
The structure of the Fyn SH3 domain has been previously
determined by X-ray crystallography [8]. Two different
structures, Fyn SH3-1 and Fyn SH3-2, were found in the
asymmetric unit, differing principally in the conformation
of b strand bb (residues 108–113). In Fyn SH3-1, this
strand extends all the way from Lys108 to Asn113; a sharp
kink in the vicinity of Leu112 divides it into substrands
bb1 and bb2, which each form part of one of the two
triple-stranded b sheets making up the classic SH3 fold.
In Fyn SH3-2, bb2 is replaced by an extended loop region
consisting of residues 111–113, which curves away from
strand bc, allowing two water molecules to come in and fill
up the resulting space. The NMR analysis which we
report here shows that only Fyn SH3-1 is found in solu-
tion. Large values of 3JHN-Ha (Ile111, 7.7 Hz; Leu112,
8.5 Hz; Asn113, 7.3 Hz) indicate a well-defined, exten-
ded conformation in this region, and protected amides 
in Leu112 and Glu121 indicate the existence of cross-
sheet hydrogen bonds, Leu112(HN) to Glu121(O) and
Glu121(HN) to Asn113(O). More importantly, strong
cross-sheet NOEs (3.50 Å) between Asn113 and Glu121
rule out the existence of interpolating water molecules.
Comparison of the rmsd values for our NMR structure
with the two crystal forms highlights this difference. The
rmsd between the backbone atoms from well defined
regions (i.e. excluding loops and strand bb) of our average
structure and both Fyn SH3-1 and Fyn SH3-2 is 0.35 Å,
indicating that the core structure is well conserved.
However, the rmsd over residues 108–113 is 0.63 Å
between our structure and Fyn SH3-2 whereas it is only
0.45 Å between our structure and Fyn SH3-1. From this,
we conclude that the Fyn SH3-2 conformation is not
significantly populated in solution.
Ser114 makes extensive contacts with the side chain of
Trp120, which possibly has a role in stabilizing the end of
bb. The amide proton of Ser114 is extensively broadened
and it functions as a hinge joining bb to a flexible loop
comprising residues 115–118. Residues in this region show
no long-range NOEs, and values of 3JHN-Ha in the region
5–8 Hz. Gly117, at the very end of the loop, is the only
residue showing a decreased 15N-1H NOE (see Fig. 1). A
hydrogen bond between Asp118(O) and Ser135(HN) in
the 310 helix stabilizes the C-terminal end of the loop,
leading into sheet bb. We note that the structure as pre-
sented here is entirely consistent with the alignment of
Kohda et al. [16]. We also agree with their classification of
the kink in sheet bb (residues 110–113) as a type 1b ‘half-
turn’ [26], due to the presence of a strong NOE cross-peak
between the amide protons of Leu112 and Asn113, and a
large 3JHN-Ha coupling in Leu112, which indicates a nega-
tive value of f for that residue. It is perhaps of interest
that the flexible loop in Fyn, which is also known as the
n-Src loop [8], occurs at the site of a 15-residue insert in
the p85a SH3 domain [16].
It has been suggested that SH3 domains may contain two
additional b strands, creating a two-stranded antiparallel
b sheet, in the long loop between strands ba and bb1 [16].
There is some suggestion of such an arrangement in Fyn
SH3, including a pair of hydrogen bonds between residues
Tyr93 and Phe103 and large 3JHN-Ha coupling constants in
some loop residues, but the evidence is insufficient to de-
fine clearly the presence of additional secondary structure.
As noted previously [5,16] there is a high degree of simi-
larity displayed in the known SH3 domain structures that
is not always reflected in the level of sequence similarity.
The majority of the differences between the known SH3
structures are restricted to the loops. The maintenance of
a fold during the evolution of such a variety of different
sequences suggests that it is inherently stable and may be
found in contexts other than proline binding. Currently
three proteins showing no sequence homology to the
SH3 domain are known to share significant structural
similarity [27–29], and this may be a topology that is
unusually favoured.
Peptide binding
In the absence of known physiological ligands, many SH3
studies have had to rely on sequences of little biological
relevance. However, it has been suggested that residues
80–104 of the p85a subunit of PI3′ kinase interact with
the SH3 domain of Fyn in vivo [24]. Two synthetic pep-
tides spanning this sequence were constructed. The first
of these, peptide 1, corresponding to residues 80–93, is
proline rich but does not contain either a class I or class II
consensus-binding sequence [21,22]. The other, peptide
2, corresponding to residues 91–104, contains the binding
site of a class I ligand. A third peptide was also synthe-
sized that is identical to peptide 2 with the exception of a
single residue mutation of Leu95→Thr. This peptide was
designed to study the role of residues other than the pro-
lines in the specificity and affinity of the SH3–peptide
interaction. The experimentally determined affinities of
all three peptides for the SH3 domain was relatively low
and intermolecular NOEs were only observed for peptide
2. Although this meant that structural details could only
be clearly resolved for one peptide, several useful observa-
tions about the other peptide complexes could be made. 
The relatively weak interaction between SH3 and the
peptides results in a fast-exchange complex (estimated to
have off-rates≥105 s–1), as observed by NMR. This allows a
detailed analysis of the binding affinity by fitting the
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change in chemical shift upon peptide binding to the
equation relating this to the Kd of the interaction (see the
Materials and methods section). The affinity of interaction
between the SH3 domain and the three peptides follows 
a trend predicted by the consensus sequences, with
peptide 1 having the lowest affinity and peptide 2 the
highest. Although peptides 2 and 3 both fit the class I con-
sensus sequence [21,22] the replacement of a leucine
residue with a threonine in peptide 3 results in approxi-
mately a fivefold decrease in affinity of this peptide for the
SH3 domain, compared with that of peptide 2. Inspection
of the peptide 2–SH3 structure (Fig. 4) indicates that the
leucine residue in position R+2 is in close contact with the
SH3 ligand-binding site. Our data suggest that the inter-
action between this position of the peptide and the SH3
module contributes significantly to affinity of the binding.
The pattern of chemical-shift changes for the amide reso-
nances of Fyn SH3 indicates that all three peptides inter-
act with the same site on the surface of the molecule
(Fig. 6). This highlights the promiscuity of the SH3–
peptide interaction: peptide 1 lacks the consensus
sequence for either a class I or a class II binding site but
still binds to the same surface on the SH3 molecule as
peptides exhibiting these consensus sequences. Although
the overall pattern of changes is the same, details of the
results for each of the peptides differ. Of greatest signifi-
cance is the difference in chemical-shift changes between
the peptide 2 and peptide 3 complexes, as these shed light
on the effect of the Leu→Thr substitution in peptide 3.
The residues most affected by the change are those that
form the binding site for residue R+2 (position PV in [23]).
This implies that peptide 3 is also binding as a class I con-
sensus ligand and that all the ligand residues in contact
with the SH3 domain contribute to the binding affinity,
not just the prolines and critical arginine. 
Biological implications
Src homology 3 (SH3) domains are present in a variety
of different proteins involved in activities as diverse 
as signal transduction and cellular structure. Conse-
quently, they take part in interactions in a number of dif-
ferent cellular environments and with a variety of
ligands. The SH3 domains of the Src family of tyrosine
kinase proteins are involved in regulation of kinase
activity, but the regulatory mechanism is unknown. We
present here a study of the structural basis for the inter-
action of the SH3 domain of Fyn, a member of the Src
family of tyrosine kinases, with peptides corresponding
to putative physiological ligand sequences.
Previously published crystallographic studies of the Fyn
SH3 domain [8] were complicated by the presence of
apparent structural heterogeneity, in that two signifi-
cantly different conformers were observed. The NMR
structures resolve this problem by demonstrating the
presence in solution of a single conformation, closely
related to one of the crystal structures. A conformation-
ally flexible loop (residues 116–118) was identified
within the structure on the basis of high root mean
square deviation between the structures and a decrease
in the 15N–1H NOE for Gly117 in the centre of the loop.
This loop is of particular interest as it has been impli-
cated in discriminating between class I and class II
ligands and is the point of insertion of additional residues
in the SH3 domains of p85a and nSrc. 
The interactions of Fyn SH3 with three different physi-
ologically relevant ligand peptides — one corresponding
to a recognizable type I consensus sequence, one a
minor structural variant of that sequence and a third
without a recognizable consensus — result in similar
patterns of chemical-shift changes. This suggests that all
the peptides bind to the same residues on the surface of
Fyn SH3. This observation — that non-consensus pep-
tides bind to the same site as higher affinity ligands —
has previously been made for the p85a SH3 domain
[11,17] and highlights the apparent promiscuity of
SH3–ligand interactions. Nonetheless, there is a correla-
tion between reduction in binding affinity and deviation
from the consensus sequence. In general, SH3–ligand
interactions appear to lack the high degree of specificity
characteristic of many other protein–protein inter-
actions; this has implications for the biological role of
SH3 domains as relatively weak promoters of protein
aggregation in signal transduction processes. 
Materials and methods
Protein production and purification
The gene for the Fyn SH3 domain (residues 82–148 of the Fyn
sequence) was encoded by a pGEX-2T plasmid and was a kind gift of
Dr C Rudd (Dana-Farber Cancer Institute, Harvard Medical School,
Boston, MA). The plasmid was transformed into E. coli cell line BL21
and protein produced by induction of plasmid gene expression in LB
broth. The production of 15N-labelled material was achieved in the
same manner except that the E. coli cells were grown in vitamin supple-
mented M8 minimal media with 15NH4Cl as the sole nitrogen source.
Protein (both labelled and unlabelled) was purified as follows: 4 h after
induction of protein expression with a final concentration of 0.1 mM
isopropyl-b-D-thiogalactopyranoside, cells were harvested by centrifu-
gation at 4°C then washed once with TTBS (50 mM Tris-HCl, pH 8.5
+ 150 mM NaCl and 0.1% (v/v) Triton X-100) then stored at –20°C
until processed. Cells were resuspended in TTBS (10 ml per gram of
cells) and then phenylmethylsulfonylflouride added to 2mM. The sus-
pension was then sonicated (5×30 s) to effect lysis of the cells.
Samples were maintained at 0°C during sonication. Cell debris was
then pelleted by centrifugation (30 min, 20 000 g) at 4°C and the 
pellet discarded. The supernatant was passed through a column of
glutathione-Sepharose beads (Pharmacia) in TTBS. After extensive
washing of the resin with TBS (TTBS without the Triton X-100) the
bound GST-SH3 fusion protein was eluted from the column with
15 mM glutathione in TBS. Fractions containing the fusion protein
(determined by measurement of the A280) were pooled and thrombin
cleavage of the fusion protein initiated by the addition of thrombin to
0.02% (w/w). Cleavage was allowed to proceed overnight, and the
extent of cleavage of the fusion protein determined by sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Cleaved
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material was then dialysed against buffer A (20 mM Tris-HCl, pH 8.5
containing 20 mM NaCl) overnight at 4°C then applied to a Mono Q
column (Pharmacia) equilibrated in buffer A. The protein was eluted
with a linear gradient from 0 to 100% buffer B (20 mM Tris-HCl,
pH 8.5 containing 500 mM NaCl) over 30 min. Fractions containing
the Fyn SH3 domain were pooled and concentrated on an Amicon
concentrator with a YM3 membrane then applied to a Sephacryl HR-
100 (Pharmacia) size exclusion column (80 ×2.6 cm) equilibrated in
50 mM Tris pH 8.0 containing 150 mM NaCl and 0.02% NaN3 for final
purification. Fractions containing pure Fyn SH3 were pooled and con-
centrated using Centriprep and Centricon concentrators (Amicon) then
buffer exchange carried out on Bio-Rad DG10 columns into 10 mM
phosphate pH 6.0 containing 0.02% NaN3. After buffer exchange,
samples were concentrated to between 2 and 3 mM for NMR. 
Purity and composition of the sample were checked by SDS-PAGE
and electron-spray mass spectroscopy (data not shown).
Nuclear magnetic resonance spectroscopy
Protein samples were prepared as described above and made to 5%
2H2O before being used for spectroscopy. Spectra were recorded at
30°C at either 500 or 600 MHz on home-built spectrometers consist-
ing of Oxford Instruments 11.7 or 14.2 Tesla magnets operated by GE
1280 computers. All spectra were recorded in phase sensitive mode
with the carrier set to the centre of the spectrum. States-TPPI acquisi-
tion [30] was used for quadrature detection in all experiments with the
CYCLOPS phase cycle used to reduce quad images. Sequential
assignment of amino acid spin systems was made from the comparison
of 3D 1H-15N NOESY-HMQC and 1H-15N TOCSY-HMQC spectra
recorded at 600 MHz [31,32]. Assignment of the side chain proton
resonances and confirmation of the sequential assignments made from
the heteronuclear spectra was carried out using 2D 1H TOCSY [33],
NOESY [34] and DQF-COSY [35] spectra recorded at 600 MHz.
3JNHa spin-spin coupling constants were derived from line-shape analy-
sis of 2D 1H-15N HMQC-J spectra [36] recorded at 500 MHz. Slowly
exchanging amide protons were distinguished by their continued pres-
ence in 2D 1H TOCSY experiments 24 h after transfer of the protein 
to 100% 2H2O. 1H-15N NOE values were determined at both 500 
and 600 MHz using the procedure of Kay et al. [37]. Data were 
processed and analyzed using the Triad and Sybyl programs (Tripos
Inc., St. Louis) on a Silicon Graphics Indigo computer.
For the peptide 2 complex, assignments were first determined for the
unliganded peptide in H2O as described for SH3, with the exception that
no heteronuclear experiments were employed. Interactions between the
peptide and SH3 were identified by analysis of 15N-decoupled NOESY
and TOCSY spectra acquired at both 30°C and 15°C on the 15N-SH3
sample used for titration with peptide 2 at a peptide:protein ratio of 4:1.
Structure calculation
A total of 588 NOEs were collected from analysis of 2D 1H NOESY
spectra recorded with 150 ms mixing time. They were broadly cate-
gorised as ‘strong’, ‘medium’, and ‘weak’, and converted to distance
upper-limit constraints 2.8, 3.5 and 5.0 Å, respectively. Only struc-
turally significant constraints were used, as determined by the program
DIANA [38]. These constraints include 103 intraresidue, 135 sequen-
tial, 55 short-range (1<i–j<5) and 295 long-range (i–j≥5) constraints.
In all cases, lower limits were taken as the sum of the van der Waals
radii of the participating atoms. Corrections were made to take account
of the positions of pseudo-atoms, and constraints involving methyl
groups were relaxed by 0.5 Å per group to compensate for the
additional intensity of the unresolved group.
A total of 100 structures was generated from extended backbone con-
formations with randomized side-chain orientations, using a modified
version of the YASAP simulated-annealing protocol in X-PLOR 3.1
[25]. These structures were then refined further by rounds of rapid sim-
ulated annealing using REFINE.INP in X-PLOR 3.1. All peptide bonds
were constrained to be in trans, and no hydrogen-bonding, electrostatic
or 6–12 Lennard-Jones empirical potential energy terms were included
in the target function. The final structural refinement was performed with
a value of k_repel of 0.75. Initially structures were built using unambigu-
ous constraints, and additional constraints added after analysis of provi-
sional structures. f-angle and hydrogen-bond constraints were added
in the final stages of refinement, based on analyses of unconstrained
structures. In residues with 3JHN-Ha>8 Hz or <5 Hz, f was constrained
to f0±30°, where f0 is the solution of the Karplus equation; when
3JHN-Ha>8 Hz, in which case there are two solutions, the one favoured
in unconstrained structures was selected. Potential hydrogen bonds
were located using software written by D Smith (unpublished program);
constraints were only added in cases where the hydrogen bond was
reliably predicted (>80%) in unconstrained structures, and the amide
proton was observed to be slowly exchanging.
The final 100 structures contained no consistent violations; from these
a family of 20 was chosen having no distance constraint-violations
greater than 0.1 Å, and no φ-constraint violations greater than 0.5°. A
representative structure was generated from the family using the
program PROBMAP [39]; it has lower energy than any of the family,
and good geometry as determined by PROCHECK_NMR [40]. Rmsd
values for the family were calculated by averaging the individual rmsds
between the average structure and each member of the family. 
The structure of the peptide 2–SH3 complex was generated as
follows. The peptide was built as a polyproline type II helix and then
docked with the representative SH3 structure on the basis of the 15
NOE interactions observed between the molecules. The complex was
then subjected to simulated annealing as described above, with the
SH3 coordinates fixed. Peptide ω angles were kept fixed at 180° and
all prolines were assumed to be trans.
Peptide binding
Peptide binding was analyzed by addition of known amounts of
lyophilized peptide to a sample of 15N-labelled SH3 of known concen-
tration. At least 12 different protein:peptide ratios were analyzed for
each interaction, ranging from 10:1 to 1:4. 1H-15N HSQC spectra were
taken after each addition and the chemical shift of each amide reso-
nance measured. Binding constants for each peptide were determined
by fitting with non-linear regression the change in chemical shift versus
peptide:SH3 ratio to the following equation: 
D=D0.
(Kd+[L]+[P])–√((Kd+[L]+[P])2–4[P][L])
2[P]
where D is the observed change in chemical shift, D0 is the total
change in chemical shift at saturation, [L] and [P] are the ligand and
protein concentrations respectively.
Accession numbers
The coordinates of both the representative structure and the family of
structures have been deposited at the PDB.
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